Key result
Global adult CKD prevalence reaches ~14%, rising relative to 1990 and causing 1.48 million deaths.
Why the study?
Chronic kidney disease is common and ranks among the leading causes of mortality and morbidity, necessitating updated global estimates to inform evidence-based policies for identification and treatment.
Systematic Review
CKD prevalence is rising globally, affecting an estimated 788 million adults in 2023, and impaired kidney function accounts for 11.5% of cardiovascular deaths.
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“South Asia has one of the highest burdens of chronic kidney disease globally, contributing to the overall risk of dyslipidemia and importance of risk stratification.”
Intensified global CKD prevention and screening are warranted; extends surveillance to 2023 and reinforces cardiovascular mortality links.
Summary Background Chronic kidney disease (CKD) is common and ranks among the leading causes of mortality and morbidity. This analysis aimed to present global CKD estimates using the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 to inform evidence-based policies for CKD identification and treatment. Methods This analysis focused on adults aged 20 years and older over the period 1990 to 2023, from 204 countries and territories. Data sources used were published literature, vital registration systems, kidney failure treatment registries, and household surveys. Estimates of CKD burden, including deaths, incidence, prevalence, and disability-adjusted life-years (DALYs), were produced using a Cause of Death Ensemble model and a Bayesian meta-regression analytical tool. A comparative risk assessment approach estimated the proportion of cardiovascular deaths attributable to impaired kidney function and estimated risk factors for CKD. Findings Globally, in 2023, 788 million (95% uncertainty interval 743–843) people aged 20 years and older were estimated to have CKD, up from 378 million (354–407) in 1990. The global age-standardised prevalence of CKD in adults was 14·2% (13·4–15·2), a relative rise of 3·5% (2·7–4·1) from 1990. The region with the highest age-standardised prevalence was north Africa and the Middle East (18·0%; 16·9–19·4). Most people had stage 1–3 CKD, with a combined prevalence of 13·9% (13·1–15·0). In 2023, CKD was the ninth leading cause of death globally, accounting for 1·48 million (1·30–1·65) deaths, and the 12th leading cause of DALYs, with an age-standardised DALY rate of 769·2 (691·8–857·4) per 100 000. Impaired kidney function as a risk factor accounted for 11·5% (8·4–14·5) of cardiovascular deaths. High fasting plasma glucose, body-mass index, and systolic blood pressure were all leading risk factors for CKD DALYs. Interpretation CKD is a major global health issue, with rising prevalence and increasing importance as a cause of death and as a risk factor for cardiovascular death. A better understating of aetiology, appropriate screening, and implementation programmes are needed to translate advances in CKD treatment into improved patient outcomes. Funding Gates Foundation, Wellcome, US National Kidney Foundation, and US National Institute of Diabetes and Digestive and Kidney Diseases.
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Mark et al. (2025) conducted a systematic review in Chronic kidney disease (CKD). Time (1990 to 2023) vs. 1990 was evaluated on Global age-standardised prevalence of CKD in adults (Relative rise of 3.5%, 95% CI 13.4-15.2). Globally in 2023, the age-standardised prevalence of chronic kidney disease in adults was 14.2%, representing a relative rise of 3.5% from 1990, and accounting for 1.48 million deaths.
Synapse has enriched 10 related papers. Consider them for comparative context: